It's a bright day on the bourse, with the All Ordinaries Index (ASX: XAO) lifting 0.37% at the time of writing. And its moves have been helped and hindered by three All Ords stocks posting some significant gains and falls.
The trio are on the move on the back of notable news. So, without further ado, let's dive into the announcements sending two stocks soaring – and one plunging – on Friday.
Image source: Getty Images
3 All Ords stocks on the move on Friday
Nickel Industries Ltd (ASX: NIC)
First up, is nickel mining company Nickel Industries. The All Ords stock is soaring 11.6% right now to trade at 96.5 cents.
It comes on news the company is raising more than $900 million through a placement wherein new shares are priced at $1.10 – a 27% premium to its previous close.
Imugene Limited (ASX: IMU)
Meanwhile, stock in All Ords biopharmaceutical company Imugene is leaping 7.5% to trade at 10 cents.
The company announced its phase one metastatic advanced solid tumours (MAST) trial, looking at the safety of its novel cancer-killing virus CF33-hNIS (VAXINIA), has progressed to the next cohort of the intravenous (IV) arms of both the monotherapy and combination study.
Imugene managing director and CEO Leslie Chong commented:
As we continue to move through the cohorts at pace, we're aiming to have this high-quality science peer reviewed and recognised within publications or conferences befitting of its results and potential benefit to patients in need.
Appen Ltd (ASX: APX)
Finally, plenty of eyes have been on ASX All Ords stock Appen lately. The company provides data and services to be used in machine learning and artificial intelligence (AI).
Unfortunately, it isn't a good day for the tech share. It's tumbling 6% right now to trade at $3.28 on news the company has completed the retail component of its capital raise.
The offer closed on Tuesday and raised around $29.5 million, with new stocks offered at $1.85 apiece. That's a near-20% discount on where the stock was trading before the capital raise was announced.
Despite that, only around 55% of eligible shareholders took up the offer, raising $15.6 million and buying 8.4 million stocks, with the remainder allotted to sub-underwriters.
